{"id":"placebo-for-ivig","safety":{"commonSideEffects":[{"rate":null,"effect":"Adverse events expected to reflect natural disease progression or trial-related procedures only"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this case, it serves as the control arm in a Phase 3 trial comparing against intravenous immunoglobulin (IVIG).","oneSentence":"A placebo control contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:13.257Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified)"}]},"trialDetails":[{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT05701189","phase":"PHASE2","title":"Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome","status":"WITHDRAWN","sponsor":"Chafic Karam","startDate":"2024-09-10","conditions":"Guillain-Barre Syndrome","enrollment":""},{"nctId":"NCT05350774","phase":"PHASE2","title":"Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-07-10","conditions":"Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis","enrollment":45},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT06599697","phase":"PHASE2","title":"The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-10-27","conditions":"Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy","enrollment":12},{"nctId":"NCT06305780","phase":"PHASE2","title":"RECOVER-AUTONOMIC Platform Protocol","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":381},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT04910269","phase":"PHASE3","title":"Outpatient Treatment With Anti-Coronavirus Immunoglobulin","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2021-08-06","conditions":"COVID, SARS-CoV2 Infection, Covid19","enrollment":820},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT04153422","phase":"PHASE2","title":"IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-15","conditions":"Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy","enrollment":20},{"nctId":"NCT01757418","phase":"PHASE1, PHASE2","title":"Intravenous Gammaglobulin for Sickle Cell Pain Crises","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2008-11","conditions":"Sickle Cell Disease, Pain","enrollment":300},{"nctId":"NCT05645107","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Grifols Therapeutics LLC","startDate":"2022-12-26","conditions":"Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia","enrollment":386},{"nctId":"NCT02176863","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome","status":"TERMINATED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-09-23","conditions":"Post-polio Syndrome","enrollment":191},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT03700138","phase":"PHASE3","title":"Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-06-19","conditions":"Primary Sjögren's Syndrome Painful Sensory Neuropathies","enrollment":24},{"nctId":"NCT06305793","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19","enrollment":200},{"nctId":"NCT06896253","phase":"PHASE2","title":"Pulse Corticosteroids Or/and Immunoglobulins to Treat Fulminant Myocarditis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-04","conditions":"Myocarditis Acute","enrollment":120},{"nctId":"NCT03919773","phase":"PHASE1, PHASE2","title":"IVIG (Gamunex-C) Treatment Study for POTS Subjects","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-10-29","conditions":"Postural Tachycardia Syndrome","enrollment":30},{"nctId":"NCT06534450","phase":"PHASE3","title":"The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dobri Kiprov","startDate":"2022-09-12","conditions":"Aging","enrollment":40},{"nctId":"NCT02308982","phase":"PHASE3","title":"Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2016-01","conditions":"Encephalitis","enrollment":18},{"nctId":"NCT06183008","phase":"PHASE4","title":"IVIG in Painful Sensory Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"Sorlandet Hospital HF","startDate":"2024-02","conditions":"Sensory Neuropathy, Small Fiber Neuropathy","enrollment":20},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT04510428","phase":"PHASE2","title":"OSIG-eye Drops Treatment for Dry Eye Disease","status":"WITHDRAWN","sponsor":"University of Illinois at Chicago","startDate":"2023-05-15","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT00841789","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease","status":"COMPLETED","sponsor":"Michael Portman","startDate":"2009-03","conditions":"Mucocutaneous Lymph Node Syndrome, Kawasaki Disease","enrollment":205},{"nctId":"NCT01769027","phase":"PHASE2","title":"Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS","status":"WITHDRAWN","sponsor":"CNS Onlus","startDate":"2013-06","conditions":"Pandas","enrollment":""},{"nctId":"NCT01376778","phase":"PHASE3","title":"A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","status":"COMPLETED","sponsor":"The George Washington University Biostatistics Center","startDate":"2012-04","conditions":"Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection","enrollment":399},{"nctId":"NCT05494619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2022-11-30","conditions":"Guillain-Barré Syndrome","enrollment":""},{"nctId":"NCT01300728","phase":"PHASE2","title":"Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Sutter Health","startDate":"2011-01-01","conditions":"Mild Cognitive Impairment","enrollment":52},{"nctId":"NCT04450654","phase":"PHASE2","title":"Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2022-05","conditions":"Immune-Mediated Necrotizing Myopathy","enrollment":""},{"nctId":"NCT04546581","phase":"PHASE3","title":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-08","conditions":"COVID, COVID-19, SARS-CoV-2","enrollment":593},{"nctId":"NCT02184741","phase":"PHASE3","title":"A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2014-06-03","conditions":"Recurrent Miscarriage","enrollment":99},{"nctId":"NCT02659891","phase":"PHASE1","title":"IVIg to Treat BK Viremia in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-05","conditions":"Kidney Transplantation, BK Virus, Isoantibodies","enrollment":16},{"nctId":"NCT00666263","phase":"PHASE3","title":"Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-08-22","conditions":"Multifocal Motor Neuropathy","enrollment":50},{"nctId":"NCT00818662","phase":"PHASE3","title":"A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-12-19","conditions":"Alzheimer´s Disease","enrollment":390},{"nctId":"NCT01524887","phase":"PHASE3","title":"Phase 3 IGIV, 10% in Alzheimer´s Disease","status":"TERMINATED","sponsor":"Baxalta now part of Shire","startDate":"2012-01-23","conditions":"Alzheimer´s Disease","enrollment":508},{"nctId":"NCT02899702","phase":"PHASE4","title":"Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-09","conditions":"Staphylococcal Infection, Streptococcal Infection","enrollment":""},{"nctId":"NCT04138485","phase":"PHASE2","title":"Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)","status":"WITHDRAWN","sponsor":"CSL Behring","startDate":"2019-12-20","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":""},{"nctId":"NCT03992482","phase":"PHASE1, PHASE2","title":"IVIG-eye Drops Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Sandeep Jain, MD","startDate":"2019-05-01","conditions":"Dry Eye","enrollment":27},{"nctId":"NCT01281969","phase":"PHASE3","title":"Intravenous Immunoglobulin for PANDAS","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2011-01","conditions":"Obsessive-Compulsive Disorder, Children, Anxiety Disorder","enrollment":48},{"nctId":"NCT02697292","phase":"PHASE3","title":"IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-02","conditions":"Autoimmune Epilepsy","enrollment":17},{"nctId":"NCT00299988","phase":"PHASE2","title":"Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2006-02","conditions":"Alzheimer's Disease","enrollment":24},{"nctId":"NCT02287467","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01","conditions":"Influenza A, Influenza B","enrollment":329},{"nctId":"NCT04041765","phase":"PHASE3","title":"IgM-Enriched Immunoglobulin for Neonatal Sepsis","status":"UNKNOWN","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2019-09","conditions":"Neonatal Sepsis, Early-Onset, Very Low Birth Weight Infant, Inflammation","enrollment":70},{"nctId":"NCT02637700","phase":"PHASE2","title":"Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy","status":"COMPLETED","sponsor":"Academisch Ziekenhuis Maastricht","startDate":"2016-07","conditions":"Small Fiber Neuropathy","enrollment":60},{"nctId":"NCT03749096","phase":"PHASE3","title":"Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2018-12-07","conditions":"Stiff-Person Syndrome","enrollment":""},{"nctId":"NCT02494505","phase":"PHASE3","title":"Interest of Mycophenolate for CIDP Weaning","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-11-18","conditions":"Chronic Inflammatory Demyelinating Polyradiculopathy","enrollment":40},{"nctId":"NCT00115778","phase":"PHASE2","title":"Intravenous Immunoglobulin (IVIG) in Lung Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":"Hypogammaglobulinemia, Lung Transplantation","enrollment":11},{"nctId":"NCT02473952","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-08","conditions":"Myasthenia Gravis, Generalized","enrollment":62},{"nctId":"NCT00892112","phase":"PHASE3","title":"Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2009-11","conditions":"Myocardial Diseases, Parvovirus B19, Human","enrollment":50},{"nctId":"NCT01785056","phase":"NA","title":"IVIG Treatment in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-04","conditions":"Systemic Sclerosis, Diffuse Scleroderma","enrollment":14},{"nctId":"NCT01545076","phase":"PHASE3","title":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy","enrollment":208},{"nctId":"NCT02788188","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-05-28","conditions":"Middle East Respiratory Syndrome Coronavirus","enrollment":38},{"nctId":"NCT01561755","phase":"PHASE4","title":"A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy","status":"TERMINATED","sponsor":"David M. Simpson","startDate":"2012-02","conditions":"HIV-associated Myelopathy","enrollment":12},{"nctId":"NCT00069316","phase":"PHASE2","title":"Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2003-09-22","conditions":"West Nile Virus","enrollment":2},{"nctId":"NCT02043379","phase":"NA","title":"Post-bypass Prophylactic IVIG in Infants and Neonates","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-05","conditions":"Hypogammaglobulinemia, Congenital Heart Disease","enrollment":50},{"nctId":"NCT02372149","phase":"PHASE4","title":"IVIg for Demyelination in Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-02","conditions":"Peripheral Neuropathy, Diabetes Mellitus, Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":25},{"nctId":"NCT00177970","phase":"PHASE4","title":"IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2003-10","conditions":"Clostridium Difficile-associated Diarrhea (CDAD)","enrollment":14},{"nctId":"NCT02008578","phase":"PHASE1","title":"Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-12","conditions":"Influenza","enrollment":31},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT02559921","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2014-12","conditions":"Rabies","enrollment":300},{"nctId":"NCT00760435","phase":"PHASE3","title":"Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2009-03","conditions":"Kawasaki Disease","enrollment":196},{"nctId":"NCT00722475","phase":"PHASE3","title":"Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2008-08","conditions":"Secondary Recurrent Miscarriage","enrollment":82},{"nctId":"NCT00335985","phase":"PHASE3","title":"Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)","status":"COMPLETED","sponsor":"Japan Blood Products Organization","startDate":"2006-06","conditions":"Polymyositis, Dermatomyositis","enrollment":26},{"nctId":"NCT01545518","phase":"PHASE2","title":"IVIG Treatment for Refractory Immune-Related Adult Epilepsy","status":"TERMINATED","sponsor":"Emory University","startDate":"2011-11","conditions":"Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder","enrollment":20},{"nctId":"NCT00812565","phase":"PHASE2","title":"Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Octapharma","startDate":"2009-02","conditions":"Alzheimer's Disease","enrollment":58},{"nctId":"NCT01628055","phase":"PHASE1","title":"IVIG in Acute Ischemic Stroke: A Pilot Study","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2013-03","conditions":"Ischemic Stroke","enrollment":""},{"nctId":"NCT01408550","phase":"PHASE3","title":"Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2011-08","conditions":"Bullous Pemphigoid","enrollment":56},{"nctId":"NCT01856205","phase":"PHASE2","title":"Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2009-05","conditions":"Japanese Encephalitis","enrollment":22},{"nctId":"NCT01315496","phase":"PHASE3","title":"GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock","status":"TERMINATED","sponsor":"Green Cross Corporation","startDate":"2009-10","conditions":"Severe Sepsis, Septic Shock","enrollment":214},{"nctId":"NCT00606905","phase":"NA","title":"Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage","status":"COMPLETED","sponsor":"University of Chicago","startDate":"1999-11","conditions":"Miscarriage, Recurrent, Abortion, Habitual","enrollment":82},{"nctId":"NCT01537575","phase":"PHASE3","title":"Intravenous Immunoglobulins for Post-Polio Syndrome","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2008-01","conditions":"Post-polio Syndrome","enrollment":50},{"nctId":"NCT01412567","phase":"NA","title":"Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2005-10","conditions":"Chronic Hepatitis B","enrollment":259},{"nctId":"NCT01006499","phase":"PHASE4","title":"Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'","status":"UNKNOWN","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","startDate":"2009-08","conditions":"Sepsis of the Newborn","enrollment":204},{"nctId":"NCT00068055","phase":"PHASE1, PHASE2","title":"IVIG - West Nile Encephalitis: Safety and Efficacy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-09","conditions":"West Nile Virus","enrollment":62},{"nctId":"NCT00809822","phase":"PHASE2","title":"Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.","status":"COMPLETED","sponsor":"Nihon Pharmaceutical Co., Ltd","startDate":"2008-11","conditions":"Bullous Pemphigoid","enrollment":20},{"nctId":"NCT00348296","phase":"PHASE3","title":"Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis","status":"COMPLETED","sponsor":"Benesis Corporation","startDate":"2006-07","conditions":"Scleroderma, Systemic","enrollment":60},{"nctId":"NCT00850005","phase":"PHASE2","title":"Intravenous Immunoglobulin (IVIG) for Resistant Neuropathic Pain","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2009-02","conditions":"Neuropathic Pain","enrollment":12},{"nctId":"NCT00004744","phase":"PHASE3","title":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1993-02","conditions":"Multiple Sclerosis","enrollment":76},{"nctId":"NCT00001550","phase":"PHASE1","title":"Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1996-04","conditions":"Muscle Rigidity, Spasm, Stiff Man Syndrome","enrollment":20},{"nctId":"NCT00004747","phase":"PHASE2","title":"Phase II Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Mucoid Exopolysaccharide Pseudomonas Aeruginosa Immune Globulin for Cystic Fibrosis","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1995-07","conditions":"Cystic Fibrosis, Bacterial Infections","enrollment":170},{"nctId":"NCT00004772","phase":"PHASE3","title":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1992-09","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":492,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for IVIG","genericName":"Placebo for IVIG","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"A placebo control contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 trial for IVIG-responsive conditions (specific indication not specified).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}